tbuckley/cabot-search huggingface dataset:
DDIS-06. Ku 70/80 IN GLIOMA - TARGETING WITH APTAMERS
Authors: Mohit Arora, Charles Davis, Timothy Dawson, Jane Alder, Clare Lawrence, Lisa Shaw
Journal: Neuro-Oncology (2016)

Aptamers are in vitro generated DNA and RNA sequences. These are randomly present in a library with common primers. Aptamer sequences have multiple permutations and combinations of nucleotides and are then ‘selected’, using Sequential Enumeration of Ligands by Exponential Enrichment (SELEX) towards the desired target, known or unknown. Modified aptamers, based on published sequences against glioma cell lines and novel aptamers were used in the project to identify and confirm the targets. Commercially available glioma cell lines and short term cultures from anonymised patient tissue were used. Fluorescent and biotin conjugated aptamers were incubated with glioma cell cultures and imaged using confocal and light microscopy. Aptamers were then reacted with glial cell lysate and subjected to precipitation using streptavidin agarose beads and gel electrophoresis. Proteins were analysed by mass spectroscopy. Ku 70 and Ku80 were identified as the most abundant protein when compared to control aptamer precipitation. Western blot analysis and siRNA knockdown was used with immunostaining, to further confirm the target. Ku70 (X-ray Repair Cross Complementing protein 6), Ku80 (X-ray Repair Cross Complementing protein 5) were precipitated along with known proteins and few unnamed proteins. Western blot analysis confirmed precipitation of Ku70 and Ku80 mainly when compared to the control aptamer. DAB staining of cell cultures revealed over-expression of Ku70 and Ku80 throughout the glioma cell cultures. siRNA knock down showed reduced binding of the aptamer to the nucleus when compared to untreated cell cultures. Certain aptamers appear to readily bind to DNA repair proteins Ku70 and Ku80 and could be used for developing targeted therapy towards glioma. Western and knockdown analysis, confirm the specificity of binding and leads the way for in-vivo testing of aptamers.
180P Clinical outcome of anal squamous cell carcinoma treated with chemoradiotherapy with 5-fluorouracil plus mitomycin C
Authors: A. Doi, H. Bando, A. Kawazoe, S. Fukuoka, Y. Kuboki, K. Shitara, W. Okamoto, T. Kojima, T. Doi, A. Ohtsu, T. Yoshino
Journal: Annals of Oncology (2016)
Usefulness of 18FDG-positron emission tomography (FDG-PET) for early prediction of erlotinib (Eb) treatment outcome in non-small cell lung cancer (NSCLC) patients: Results of a pilot study
Authors: H. J. Soto Parra, M. Ippolito, M. Tiseo, S. Cosentino, A. Ardizzoni, F. Latteri, V. Pumo, S. Cordio, R. Bordonaro, P. Spadaro
Journal: Journal of Clinical Oncology (2009)

7568 Background: FDG-PET could be useful for early evaluation of tumor response to tyrosine kinase inhibitors (TKI). Glucose metabolic activity seems to closely reflect response to epidermal growth factor receptor (EGFR) TKI in vivo and in vitro (Su H et al, Clin Cancer Res 2006;12:5659–67). Thus, we attempted to assess the clinical value of FDG-PET for early prediction of tumor response to Eb an EGFR-TKI. Methods: Pts with NSCLC stage IV in progression after at least one line of chemotherapy and PS 0–1 were treated with Eb (150 mg orally once daily). FDG-PET was performed on days 0 and 2, after administration of 3 daily doses. FDG uptake was evaluated as the maximum standardized uptake value in the tumor (SUVmax). SUVmax was divided by SUV of the background region (liver) to produce the tumor:nontumor ratio (TNT). FDG-PET responses were evaluated by quantitative changes on TNT and classified according to the EORTC PET study group. PET response were compared with radiographic tumor response (RECIST criteria) assessment based on CT scan at baseline and on day 45. Results: From May 2007, 27 pts were enrolled and 23 were evaluable (4 not-evaluable: 2 BAC PET negative, 2 violations). FDG-PET revealed a metabolic partial response (PR) in 8 pts; subsequent CT scan assessment evidenced 4 PR and 4 long lasting stable disease (SD), respectively. Seven pts had metabolic progressive disease (PD) at PET scan and 8 had SD, all of them presented PD at CT scan. Metabolic PR was associated with a longer median progression-free survival (152 vs 45 days, p = &lt; 0.0001) and longer overall survival (323 vs 128 days p=0.15). For radiological PD pts who presented metabolic SD or PD, survival time was respectively 220 and 117 days. EGFR gene mutation, gene copy number and protein expression are ongoing. Conclusions: FDG-PET using changes on TNT can very early predict (already 2 days after initiation) Eb treatment outcome. Particularly, pts with early metabolic PD are unlikely to benefit from Eb. Therefore, evaluation of the early metabolic response holds promise for assessment of pts selection. The two different behavior of FDG-PET observed on refractory pts, deserve biomolecular analysis for understanding mechanism of resistance. No significant financial relationships to disclose.
The Higher CD34+ Cell Counts in Cord Blood Than Those in Neonatal Peripheral Blood Correlate with Increased Expression of Cytokine Receptors and Cell Adhesion Molecules on the CD34+ Cells in Cord Blood.
Authors: Young-Ho Lee, Joong-Pyo Kim, Myung-Hwa Sung, Ri-Young Ko, Jin-Yeong Han
Journal: Blood (2004)
Changes in Perioperative Antibiotic Use When Utilizing Preoperative Penicillin Allergy Testing For Patients With History of Allergy to Penicillin
Authors: Keith A. Sacco, Eduardo Rodrigues, Joan Irizarry Alvarado, Denice Moon, Andrea Davidson, Thanai Pongdee
Journal: Journal of Allergy and Clinical Immunology (2017)
IL-10 Prevents the Production of Type 2 Cytokines in Human Group 2 Innate Lymphoid Cells
Authors: Noriko Ogasawara, Julie A. Poposki, Aiko I. Klingler, Bruce K. Tan, Kathryn E. Hulse, Whitney W. Stevens, Anju T. Peters, Leslie C. Grammer, Robert P. Schleimer, Kevin C. Welch, Stephanie S. Smith, David B. Conley, Pejman Soroosh, Tetsuo Himi, Robert C. Kern, Atsushi Kato
Journal: Journal of Allergy and Clinical Immunology (2017)
Health-related quality of life in underserved patients with hematologic malignancies.
Authors: Muhammad Umair Umair Mushtaq, Ankit Mangla, Hussein Hamad, Sharad Khurana, Rosalind Catchatourian
Journal: Journal of Clinical Oncology (2016)

238 Background: Patients diagnosed with hematologic malignancies have poor general health and the issues faced by vulnerable population segments further aggravate the situation. We aimed to explore the health-related quality of life (HRQoL) among underserved patients with hematologic malignancies. Methods: A cross-sectional study, including 95 patients diagnosed with hematologic malignancy, was conducted at Cook County Hospital, Chicago from Dec. 2014 to July 2015. European Organization for Research and Treatment of Cancer questionnaire was used to ascertain HRQoL. A standardized score (scale 0-100) was calculated for all variables and mean scores (MS) are reported. Higher score for HRQoL and functional scales and lower score on symptom scales indicated good health. Bivariate analysis, using t-test and ANOVA, was conducted to explore predictors of HRQoL. Results: The study included 48% Hispanics, 27% Afro-Americans, 14% Asians and 7% Caucasians. Median age was 53.8 years and 55% were males. Demographic analysis showed- 47% were fluent in english, 40% had insurance, 56% were US citizens, 14% were employed, 33% were high school graduates and 79% had good social support. Primary diagnosis were non-Hodgkin lymphoma (29.5%), AML (26%), ALL (17%), CML (9.5%), Hodgkin lymphoma (9.5%), CLL (4%) and multiple myeloma (4%). Median time since diagnosis was 2 years where 35% patients were in remission, 16% had relapsed disease and 58% were on chemotherapy. Overall HRQoL was poor (MS 62). Functional impairment was noted (MS 69) in all aspects including physical (MS 72), role (MS 66), emotional (MS 70), cognitive (MS 74) and social functioning (MS 65). Financial difficulties (MS 54), insomnia (MS 35), pain (MS 32), dyspnea (MS 24), poor appetite (MS 24), constipation (MS 23), fatigue (MS 17) and diarrhea (MS 14) were reported (symptom scale MS 29). Age, gender, socio-demographics, cancer type and treatment status did not significantly affect HRQoL, functional and symptom scores. Information regarding the disease was poor (MS 41). Conclusions: Poor HRQoL amongst underserved patients was observed which should be addressed. Our findings warrant large-scale studies to explore resources amongst the urban underserved blood cancer patients.
The Role of FcγRIIa and TGF-β1/KLF6 Pathway in Platelet's Promoting Hepatocellular Carcinoma Cells Growth
Authors: Ao-Di He, Ming-Lu Liang, Gang Liu, Xing-Wen Da, Guang-Qiang Yao, Wen Xie, Ji-Zhou Xiang, Cunji Gao, Zhang-Yin Ming
Journal: Blood (2014)
Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes
Authors: Josep M. Anto, Jean Bousquet, Mubeccel Akdis, Charles Auffray, Thomas Keil, Isabelle Momas, Dirkje S. Postma, Rudolf Valenta, Magnus Wickman, Anne Cambon-Thomsen, Tari Haahtela, Bart N. Lambrecht, Karin C. Lodrup Carlsen, Gerard H. Koppelman, Jordi Sunyer, Torsten Zuberbier, Isabelle Annesi-Maesano, Albert Arno, Carsten Bindslev-Jensen, Giuseppe De Carlo, Francesco Forastiere, Joachim Heinrich, Marek L. Kowalski, Dieter Maier, Erik Melén, Henriette A. Smit, Marie Standl, John Wright, Anna Asarnoj, Marta Benet, Natalia Ballardini, Judith Garcia-Aymerich, Ulrike Gehring, Stefano Guerra, Cynthia Hohmann, Inger Kull, Christian Lupinek, Mariona Pinart, Ingebjorg Skrindo, Marit Westman, Delphine Smagghe, Cezmi Akdis, Niklas Andersson, Claus Bachert, Stephane Ballereau, Ferran Ballester, Xavier Basagana, Anna Bedbrook, Anna Bergstrom, Andrea von Berg, Bert Brunekreef, Emilie Burte, Kai-Hakon Carlsen, Leda Chatzi, Jonathan M. Coquet, Mirela Curin, Pascal Demoly, Esben Eller, Maria Pia Fantini, Leena von Hertzen, Vergard Hovland, Benedicte Jacquemin, Jocelyne Just, Theresa Keller, Renata Kiss, Manolis Kogevinas, Sibylle Koletzko, Susanne Lau, Irina Lehmann, Nicolas Lemonnier, Mika Mäkelä, Jordi Mestres, Peter Mowinckel, Rachel Nadif, Martijn C. Nawijn, Johan Pellet, Isabelle Pin, Daniela Porta, Fanny Rancière, Emmanuelle Rial-Sebbag, Yvan Saeys, Martijn J. Schuijs, Valerie Siroux, Christina G. Tischer, Mathies Torrent, Raphaelle Varraso, Kalus Wenzel, Cheng-Jian Xu
Journal: Journal of Allergy and Clinical Immunology (2017)
CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG).
Authors: Christina Nickenig, Martin H. Dreyling, Eva Schiegnitz, Michael Pfreundschuh, Lorenz H. Truemper, Marcel Reiser, Hannes Wandt, Eva Lengfelder, Wolf-Dieter Ludwig, Wolfgang E. Berdel, Bernd Metzner, Georg Hess, Roswitha Forstpointner, Reza Parwaresch, Joerg Hasford, Michael Unterhalt, Wolfgang Hiddemann
Journal: Blood (2004)
Benralizumab Reduces Exacerbations in Japanese Patients with Severe, Uncontrolled Asthma: Subgroup Analysis of the Calima Trial
Authors: J Mark FitzGerald, Ken Ohta, Mitsuru Adachi, Yuji Tohda, Tadashi Kamei, Motokazu Kato, Masayuki Takanuma, Tadahiro Kakuno, Nobuyuki Imai, Yanping Wu, Magnus Aurivillius, Mitchell Goldman
Journal: Journal of Allergy and Clinical Immunology (2017)
Nanoplasmonic quantification of tumour-derived extracellular vesicles in plasma microsamples for diagnosis and treatment monitoring
Authors: Kai Liang, Fei Liu, Jia Fan, Dali Sun, Chang Liu, Christopher J. Lyon, David W. Bernard, Yan Li, Kenji Yokoi, Matthew H. Katz, Eugene J. Koay, Zhen Zhao, Ye Hu
Journal: Nature Biomedical Engineering (2017)
Efficacy and safety of radioiodine in the treatment of disseminated differentiated thyroid cancer (DTC) in children
Authors: D. Handkiewicz-Junak, J. Roskosz, A. Kropinska, J. Kozielski, A. Krzywiecki, J. Krajewska, J. Krajewska, Z. Puch, T. Olczyk, B. Jarzab
Journal: Journal of Clinical Oncology (2009)

10065 Background: Distant metastases, mainly to lung are diagnosed in about 20% of children with DTC. At present radioiodine is the treatment of choice in that case. However, it can results in massive lung fibrosis as was showed in historical groups of patients.The aim of this retrospective study was to evaluate results of radioiodine therapy in children and its long-term safety. Methods: From 235 children (median age 13.9) diagnosed either with papillary (82%) or follicular cancer (18%), 42 (17.9%) had lung, and 2 (9%) bone metastases (median time of observation 105 months). All were treated with radioiodine (accumulated activities 100 to 950 mCi). Treatment results were evaluated by means of scintigraphic, radiological, and biochemical examinations. 28 (67%) of the children were lately re-evaluated with high resolution CT, ultrasound, biochemistry, and spirometry. Results: In most children, 29/44 (66%), distant metastases were diagnosed in radioiodine scan while radiological examinations were normal. Complete scintigraphic and radiological remission was achieved in 38 (86%) children. In all children there was a decrease in thyroglobulin serum concentration after radioiodine therapy. However, it normalized at the last radioiodine treatment only in 13 (29%) cases. During follow-up Tg continued to decrease and at the last stimulated Tg evaluation it was &lt; 10 ng/ml in 28 (64%) patients. In 5/28 (18%) of the children with lung metastases some small foci of focal lung fibrosis were diagnosed with CT. However, comparable percentage of focal fibrosis was observed in DTC children without lung metastases. Also the preliminary results didn't show an increased rate of abnormal spirometry results. Conclusions: Complete remission of distant metastases can be achieved in about 85% of children with DTC treated with radioiodine. This therapy is safe and does not cause any increased risk of lung fibrosis even in children treated with repeated courses of radioiodine. No significant financial relationships to disclose.
First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Authors: F.-C. Bidard, E. Brain, W. Jacot, T. Bachelot, S. Ladoire, H. Bourgeois, A. Gonçalves, H. Naman, J. Gligorov, F. Dalenc, C. Levy, M. Espie, J.-M. Ferrero, E. Luporsi, M.-P. Sablin, C. Dubot, M. Chevrier, F. Berger, C. Alix-Panabieres, J.-Y. Pierga
Journal: Annals of Oncology (2016)
CD8+ Central Memory T Cells Mediate Graft-Versus-Host Disease Although Retain Graft-Versus-Leukemia Effect.
Authors: Hong Zheng, Catherine C. Matte, Britt E. Anderson, Srividhya Venkatesan, Dhanpat Jain, Mark J. Shlomchik, Warren D. Shlomchik
Journal: Blood (2005)
Pilot study of cisplatin, 5-fluorouracil, and a taxane (TPF) for advanced squamous cell carcinoma (SCC) of the penis.
Authors: R. Salvioni, N. Nicolai, L. Piva, M. Catanzaro, T. Torelli, D. Biasoni, S. Stagni, A. Milani, A. Necchi
Journal: Journal of Clinical Oncology (2011)

4639 Background: Treatment of patients (pts) with advanced penile SCC is very often unsuccessful. Single agents or combination therapies (Rx) combined with surgery achieved unsatisfactory results. We evaluated TPF in either neoadjuvant (NA), adjuvant (A) or metastatic (M) setting in a single-center pilot trial. Methods: 3-4 courses of paclitaxel 120 mg/m2 d1 or docetaxel 75 mg/m2 d1 + cisplatin 75 mg/m2 d1 + 5-fluorouracil (5FU) 96 hrs continuous infusion 750 mg/m2 from d1, q3wks were provided. Primary endpoint (EP) was progression-free survival (PFS). Safety profile, RECIST v.1.0 response rate (RR) and overall survival (OS) were the secondary EP. Results: From 7/2004 to 12/2010, 40 consecutive pts were treated, 34 of them fully evaluable for response and outcome. 8 pts underwent paclitaxel-PF and 26 docetaxel-PF. Grade ≥ 3 renal and neurotoxicity were recorded in 1 patient each. Adjuvant setting: 16 pts (4 bilateral and 14 pelvic pN2-3) underwent adjuvant TPF. Median PFS and OS were 7 mos (IQR 4-9) and 9.5 mos (IQR 4-17.5). 11 (69%) are alive after 7 mos (IQR 4-21.5) of median follow-up (f-u). No difference was recorded according to bilateral or pelvic disease. Neoadjuvant setting: 12 pts with cN2/3 M0 SCC (9 cN3) were treated. 4 of them (33%) had a nodal relapse after prior lymphadenectomy. Median PFS was 5 months (IQR 2-7.2). Three pts achieved a complete response (CR) and 4 pts achieved a partial response (PR, response rate-RR=58%). OS was 5 mos (IQR 2.7-9.2). 11/12 pts underwent surgery which was radical in 9 (75%). 2 pathologic-CR (17%) have been achieved. 6 pts (50%) are alive after a median f-u of 4.5 mos (IQR 2.5-6). Metastatic setting: 6 patients were treated. One (17%) had a PR and all died of disease. Median PFS and OS were 2 mos (IQR 1.2-2.7) and 5 mos (IQR 4.3-7.3). Median PFS and OS in the whole series were 6 (IQR 4-8) and 6.5 mos (IQR 3-12) respectively. Conclusions: Perioperative TPF showed activity in advanced penile SCC. It deserves further investigation in earlier disease stages (cN1-2), combined with surgery. An expansion cohort in NA setting is ongoing. Neoadjuvant TPF allowed to obtain a significant number of responses and to perform radical surgery even in nodal relapses after prior intervention.
Variability in Exposure of Epitope G40-R43 of Domain I in Commercial Anti-β2-Glycoprotein I IgG Elisas Influences the Diagnosis of the Antiphospholipid Syndrome
Authors: Leonie Pelkmans, Hilde Kelchtermans, Marisa Ninivaggi, Theo Lindhout, Philip G de Groot, Vittorio Pengo, Bas De Laat
Journal: Blood (2012)
Epidemiological Study and Prognostic Markers in Patients Diagnosed with Chronic Ly Lmphocytic Leukemia. EPIGEN Study.
Authors: Mariola Abio, Gonzalo Caballero, Francisco Sala, Guillermina Hurtado, Jose A Marquez, Victoria Dourdil, Susana Arambarri, Filomena Floristan, Nicolas Gonzalez, Roberto Hernandez, Luis Lopez, Luis Perdiguer, Javier Marco, Francisco Sancho, Ignacio Olalla, Pilar Giraldo
Journal: Blood (2009)
The Comparative Analysis of Bone Marrow Transplantation and Cord Blood Transplantation from Unrelated Donors in Patients with Myelodysplastic Syndrome in Japan.
Authors: Satoshi Takahashi, Takuhiro Yamaguchi, Jun Ooi, Akira Tomonari, Nobuhiro Tsukada, Takaaki Konuma, Tokiko Nagamura, Shunichi Kato, Takakazu Kawase, Yasuo Morishima, Shigetaka Asano
Journal: Blood (2007)
Principal results of the cancer of the ovary abiraterone trial (CORAL): A phase II study of abiraterone in patients with recurrent epithelial ovarian cancer (CRUKE/12/052)
Authors: S. Banerjee, L. Kilburn, R. Bowen, H. Tovey, M. Hall, S. Kaye, G. Rustin, M. Gore, J. McLachlan, A. Attygalle, N. Tunariu, J.P. Lima, P. Chatfield, L. Jeffs, E. Folkerd, M. Hills, S. Perry, G. Attard, M. Dowsett, J. Bliss
Journal: Annals of Oncology (2016)
Circulating free tumour-derived DNA (ctDNA) to detect EGFR mutation in patients (pts) with advanced NSCLC (aNSCLC): French subset analysis of the ASSESS study
Authors: M.G. Denis, M.P. Lafourcade, G. Le Garff, C. Dayen, L. Falchero, P. Thomas, C. Locher, G. Fraboulet, G. Oliviero, M. Licour, N. Normanno, M. Reck, O. Molinier
Journal: Annals of Oncology (2016)
High Risk Diffuse Large B Cell Lymphoma: A Comparison of Aggressive Subtypes Treated with Dose Adjusted Chemotherapy-the University of Texas MD Anderson Experience
Authors: Vishwanath Sathyanarayanan, Yasuhiro Oki, Amir K Issa, Mohamed Amin Ahmed, Mansoor Noorani, Michelle A Fanale, Fredrick B. Hagemeister, Sattva S. Neelapu, Loretta J. Nastoupil, Nathan Fowler, Francesco Turturro, Eric Richard Davis, Alma Rodriguez, Michael Wang, Lei Feng, Ken H. Young, Timothy J. McDonnell, Chelsea C Pinnix, Luis E. Fayad, Jason R. Westin
Journal: Blood (2016)
Comparison of NSAID Hypersensitivity Between Children and Adolescents.
Authors: Diana Pérez-Alzate, Natalia Blanca-Lopez, Jose Antonio Cornejo, Maria Luisa Somoza, Francisco Javier Ruano, Elisa Haroun, Natalia I. Perez-Sanchez, Francisco Rivas, Miguel Blanca, Gabriela Canto
Journal: Journal of Allergy and Clinical Immunology (2017)
Association of hypothyroidism with improved outcomes in first-line treatment of renal cell carcinoma with sunitinib.
Authors: Flavio Augusto Ismael Pinto, Augusto Akikubo Rodrigues Pereira, Maria Nirvana Formiga, Marcello Ferretti Fanelli, Ludmilla T. D. Chinen, Vladmir C. Lima, Debora De Melo Gagliato, Elzabeth Santana Santos, Aldo A. Dettino, Carlos Eduardo Pires Sousa, Newton Augusto Ferreira Rodrigues, Fernando Vidigal Padua, Paulo Henrique Aires Freitas, Marclesson S. Alves, Ulisses Ribaldo Nicolau, Joyce Lisboa, Adriana G. Ribeiro, Victor Hugo Fonseca Jesus, JosÃƒÂ© A. Rinck
Journal: Journal of Clinical Oncology (2012)

466 Background: Sunitinib, a multitarget tyrosine-kinase inhibitor, has become a standard of care for first-line low and intermediate risk metastatic renal cell carcinoma (mRCC). Sunitinib-induced hypothyroidism and hypertension have been correlated with better outcomes in those patients. Methods: Fifty patients with mRCC, treated in the first-line with sunitinib, were retrospective analyzed at one brazilian institution, for overall survival (OS), progression free survival (PFS), overall response rate (ORR) and toxicity. We evaluated clinical and laboratory parameters, such as hypothyroidism (TSH level &gt; 5,5 mIU/L) and hypertension, to identify prognostic factors. Results: The median age of patients was 58 years (range: 37-73 years), 82% were male, 54% were ECOG 0 or 1, and 76% were classified in low or intermediate risk. Nefrectomy was performed in 96% of cases. Lung and bone were the most common sites of metastases. The incidence of hypothyroidism and hypertension during treatment were 40% and 34%, respectively. ORR for the entire population was 40% and it was statistically superior in patients that developed hypothyroidism during treatment (90% vs. 20%; p&lt;0,0001). Median survival and PFS were 21.7 months (10.65-17.70 months, 95% CI) and 14.2 months (15.77-27.58 months, 95% CI), respectively. In univariate analysis, ECOG (p&lt;0,0001), MSKCC criteria (p&lt;0,0001), hypothyroidism (p&lt;00001) and hypertension (p=0,001) were associated with OS. In multivariate analysis, ECOG (p&lt;0,0001), MSKCC criteria (p&lt;0,0001) and hypothyroidism (p&lt;00001) were independent prognostic factors for OS. The most common severe adverse events (G3-4) were asthenia (14%), diarrhoea (6%), neutropenia (14%), thrombocytopenia (10%), hand-foot syndrome (6%) and hypertension (8%). Conclusions: Efficacy in survival and toxicity profile of sunitinib in first-line treatment of mRCC in patients out of clinical trials were comparable to prior studies. Hypothyroidism, MSKCC criteria and ECOG were independent prognostic factors for survival.
Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results
Authors: Partow Kebriaei, Roland L. Basset, Celina Ledesma, Gabriela Rondon, Betul Oran, Stefan O. Ciurea, Amin M. Alousi, Uday R. Popat, Krina K Patel, Sairah Ahmed, Amanda L. Olson, Qaiser Bashir, Nina Shah, Roy Jones, Katy Rezvani, Yago Nieto, Issa F. Khouri, Muzaffar H. Qazilbash, Chitra M. Hosing, Elizabeth J. Shpall, Richard E. Champlin, Borje S. Andersson
Journal: Blood (2015)
High ZAP-70 and Differential Expression of B-Cell Receptor Related Genes in Chronic Lymphocytic Leukemia with V3-21 Gene Usage.
Authors: Dirk Kienle, Alexander Kröber, Dirk Winkler, Daniel Mertens, Annett Habermann, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer
Journal: Blood (2004)